Klaria Pharma readies the European rollout of its migraine treatment SAF while advancing strategic US expansion plans and M&A discussions with BDO to unlock global asset value.
Klaria is entering a pivotal commercial phase with the imminent European launch of its Sumatriptan Alginatfilm (SAF) through partner CNX Therapeutics. The company has also finalized a strategic plan for a potential US market entry, which, combined with ongoing M&A advisory from BDO, is intended to maximize shareholder value through licensing or asset sales. These developments are supported by a current rights issue aimed at strengthening the balance sheet to improve negotiating leverage.
L.E.K. Consulting estimates potential annual peak sales of approximately 500 million USD.
Klaria has completed necessary FDA meetings, confirmed no further bioequivalence studies are needed, and only requires one minor tolerance study before filing.
Klaria will receive milestone payments upon achieving reimbursement levels in each country, plus a double-digit royalty on sales.
Klaria Pharma is preparing for the imminent European launch of its Sumatriptan Alginatfilm (SAF) for migraine treatment through partner CNX Therapeutics. Simultaneously, the company has finalized a strategic plan for a potential US market entry and is working with BDO to explore licensing deals or corporate transactions to maximize shareholder value.
SAF is approved in key European markets including Germany, Spain, and Italy, with partner CNX Therapeutics currently finalizing commercial preparations for an imminent launch.
Klaria is working with BDO's life science M&A division to explore licensing deals or corporate transactions for markets outside Europe, specifically the US and global territories, to maximize shareholder value.